Australian biotech firm CSL tanks 17% after CEO departure, weak first-half earnings
10/02/2026 23:09
Feb 11 (Reuters) - Shares of Australia's CSL Ltd CSL.AX plunged more than 17% in early trading on Wednesday after the biotech giant announced the departure of its chief executive officer, Paul McKenzie, and reported a 7% drop in its first-half earnings. CSL's shares plunged 17.6% to A$151.350, their lowest since mid-February 2018. (Reporting by Kumar Tanishk in Bengaluru; Editing by Alan Barona) ((Tanishk.Kumar@thomsonreuters.com; X: @thatstanishk;))
Recent news on Csl
See all newsEU Commission opens antitrust probe into Sanofi's flu vaccine campaign (updated)
EU Commission opens antitrust probe into Sanofi's flu vaccine campaign
Analysis: US prices for new drugs fell in 2025 as fewer costly gene therapies were launched
US military requires flu vaccine for some after outbreak in Texas training center
Corrected: BUZZ-Australian healthcare stocks hit a six-week high, acting as a primary hedge on ASX